Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic.

Druce, Katie L; Iqbal, Kundan; Watson, Kath D; Symmons, Deborah P M; Hyrich, Kimme L; Kelly, Clive.

Afiliação

Druce KL; Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
Iqbal K; Department of Rheumatology, Queen Elizabeth Hospital, Gateshead, UK.
Watson KD; Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
Symmons DPM; Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
Hyrich KL; National Institute of Health Research Manchester Musculoskeletal Biomedical Research Unit, Central Manchester Foundation Trust and University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
Kelly C; Department of Rheumatology, Queen Elizabeth Hospital, Gateshead, UK.

RMD Open ; 3(1): e000473, 2017.

Article em En | MEDLINE | ID: mdl-28955489